Inhibitor Therapeutics Business Summary

Inhibitor Therapeutics, Inc. (INTI) is a clinical-stage biopharmaceutical company that operates on a development-to-commercialization business model centered on repurposing established active pharmaceutical ingredients (APIs) for novel, patent-protected indications. The company primarily generates value through the clinical advancement of its lead candidate, a proprietary oral formulation of itraconazole, targeting two core business segments: orphan-designated proliferation disorders, specifically Basal Cell Carcinoma Nevus Syndrome (Gorlin’s syndrome), and oncology indications including metastatic prostate and non-small cell lung cancers. INTI’s market strategy focuses on providing a better-tolerated, chronic alternative to existing hedgehog pathway inhibitors that are often limited by high toxicity. It competes directly with Sol-Gel Technologies, which is developing patidegib (SGT-610), as well as established pharmaceutical giants Roche (Genentech) and Novartis, which market the hedgehog inhibitors Erivedge and Odomzo, respectively. Relative to these competitors, INTI positions itself as a niche developer of bioavailable, repurposed therapies designed for long-term disease management in rare patient populations. The company is led by Founder, Executive Chairman, and CEO Dr. Francis E. O’Donnell, Jr., a Johns Hopkins-trained ophthalmologist and prolific medical entrepreneur who previously founded BioDelivery Sciences International (BDSI) and Laser Vision Centers. Supporting the executive suite is Interim CFO James A. McNulty, a CPA with extensive biopharmaceutical experience who formerly served as CFO of BioDelivery Sciences and MIRA Pharmaceuticals. The leadership team is further bolstered by a Scientific Advisory Board chaired by Dr. Elizabeth Billingsley. Following a pivotal 2022 legal settlement that restructured the company’s ownership, HedgePath LLC (HPLLC) emerged as the controlling shareholder, holding approximately 63% of the equity. The Board of Directors includes key figures such as Samuel Sears, Esq., and Dr. Niraj Vasisht, ensuring a blend of legal, financial, and technical oversight as the company advances its new proprietary formulation toward Investigational New Drug (IND) milestones.